Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-05
2006-09-05
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253050, C544S121000, C544S363000
Reexamination Certificate
active
07101881
ABSTRACT:
The present invention relates to compounds of formula Iwherein X and Y are as defined in the specification, and to pharmaceutical compositions comprising the compound of formula I and a pharmaceutically effective carrier; and to a method useful in treating or preventing in mammals, including humans, a disorder or condition selected from the group consisting of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias.
REFERENCES:
patent: 6313118 (2001-11-01), Berg et al.
patent: 03037887 (2003-05-01), None
K. Rasmussen et al.,Recent Progress in Serotonin(5-HT)1AReceptor Modulators,Ann. Rap. Med. Chem., 1, 30, 1-9 (1995).
R. Sharma et al.,5-HT 1B Receptor System: Possible Implications for Schizophrenic Negative SymptomatologyPsychiatric Annals, 26, 88-92 (1998).
S. Ramboz, et al.,5-HT1B receptor knock out-behavioral consequences,Behav. Brain Res., 73, 305-312 (1996).
Bernhardt Emily
Hosley Mary J.
Pfizer Inc
Zelson Steve T.
LandOfFree
Tetrahydroquinolines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydroquinolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydroquinolines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3594379